MK-677 (Ibutamoren) — Research Reference

MK-677 (also known as Ibutamoren, or by the research designation MK-0677) is a non-peptide, orally active ghrelin receptor agonist and growth hormone secretagogue. It is not a peptide — it is a small molecule drug belonging to the spiropiperidine class — but it is commonly included alongside peptide GH secretagogues in research contexts because it acts on the same GHS-R1a (ghrelin receptor) target as the GHRP peptide class.

Important classification note: MK-677 is a synthetic small molecule, not a peptide. Its classification alongside GHRP peptides on this site reflects its shared receptor target and overlapping research applications, not structural similarity. It is not administered by injection and does not require reconstitution.

Quick Reference

Overview

MK-677 was developed in the 1990s by Merck Research Laboratories as an oral alternative to injectable GH secretagogues. Its key pharmacological advantage over peptide GHRPs is oral bioavailability: peptides such as Ipamorelin and GHRP-2 are enzymatically degraded in the gastrointestinal tract and require injection; MK-677’s small molecule structure resists this degradation and is absorbed orally with substantial bioavailability.

MK-677 binds the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, mimicking ghrelin’s action and stimulating pulsatile GH release. Unlike peptide GHRPs, which have half-lives of 15–120 minutes requiring multiple daily injections, MK-677’s ~24-hour half-life enables once-daily oral dosing that produces sustained elevation of GH and downstream IGF-1.

Human research with MK-677 is more extensive than for most peptide secretagogues. Controlled clinical trials have investigated MK-677 for GH deficiency in adults and children, muscle wasting in the elderly, hip fracture recovery, Alzheimer’s disease, and obesity. These studies have provided human pharmacokinetic, efficacy, and safety data that inform anecdotal research protocols.

Reported Protocols

Oral Administration

MK-677 is taken orally as a tablet or liquid formulation. Commonly reported doses range from 10 mg to 25 mg per day.

• Starting dose: Many research accounts describe beginning at 10 mg per day to assess tolerability before increasing, particularly given the pronounced appetite stimulation that is commonly reported.
• Standard research dose: 25 mg per day, taken once daily, is the most frequently cited dose in research literature and anecdotal accounts.
• Evening administration: Taking MK-677 in the evening before sleep is a commonly reported approach, intended to amplify the largest natural GH pulse that occurs during slow-wave sleep.
• Cycle duration: Commonly reported cycles range from 8 weeks to 6 months or longer. Some accounts describe year-round use; the long-term safety profile in humans is not fully characterised.
• No injection or reconstitution: MK-677 does not require reconstitution, syringes, or injection — a key practical distinction from all peptide GH secretagogues.

Reported Effects

GH and IGF-1 Elevation

Research has investigated MK-677 for its potential role in elevating serum GH and IGF-1. Clinical studies have consistently demonstrated meaningful GH and IGF-1 elevation across multiple weeks of administration. A 2009 study in growth hormone-deficient adults reported IGF-1 normalization with 25 mg daily MK-677. IGF-1 elevation is sustained throughout the dosing period, unlike the transient GH pulses produced by injectable GHRPs, because the ~24-hour half-life maintains persistent GHS-R1a stimulation.

Muscle Mass and Lean Body Mass

Research has investigated MK-677 for its potential role in increasing lean body mass and reducing lean mass loss in conditions of caloric restriction or aging-associated muscle wasting. A 2-year randomized trial in healthy elderly adults reported significant increases in lean body mass and basal metabolic rate. An 8-week study in healthy young men reported significant increases in lean body mass compared to placebo.

Sleep Quality

Research has investigated MK-677 for its potential role in sleep quality, particularly slow-wave (stage 3) sleep architecture. A study published in 1997 reported significant improvements in sleep quality and slow-wave sleep duration in both healthy young men and elderly subjects. Anecdotal research accounts consistently describe improved sleep quality and more vivid dreams as among the most commonly reported subjective effects.

Appetite Stimulation

Research has investigated MK-677 for its pronounced appetite-stimulating effect via ghrelin receptor activation in the hypothalamus. Like GHRP-6, MK-677 produces significant hunger, which is reported in both clinical studies and anecdotal accounts. This effect is dose- dependent and is among the most consistently reported subjective effects. It is simultaneously documented as a potential utility (where increased caloric intake and lean mass accrual are research goals) and a commonly reported challenge for researchers who are not seeking caloric surplus.

Bone Density

Research has investigated MK-677 for its potential role in bone density, with studies reporting improvements in bone mineral density markers in elderly populations and a study in hip fracture patients reporting reduced adverse outcomes. These effects are mediated downstream through IGF-1’s bone-trophic properties.

Potential Neuroprotective Role

Research has investigated MK-677 for its potential role in cognitive function. A small clinical trial investigated MK-677 in patients with Alzheimer’s disease. Preclinical data has proposed IGF-1 as a mediator of neuronal maintenance and repair, providing the mechanistic rationale for investigation.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following.

Insulin resistance consideration: Clinical studies have reported that MK-677 can produce transient increases in fasting blood glucose and insulin at doses of 25 mg or higher, particularly in older populations or those with metabolic risk factors. This is consistent with GH’s known insulin-antagonising properties. Research accounts frequently describe monitoring fasting glucose when using MK-677 at higher doses or over prolonged periods.

Not for certain populations: Clinical trials have excluded individuals with active malignancy (given concerns about IGF-1’s mitogenic effects), significant insulin resistance, and type 2 diabetes from MK-677 studies. These exclusions reflect the safety considerations standard to any GH-elevating intervention.

Storage & Handling

MK-677 is typically supplied as tablets, capsules, or a liquid solution — not as a lyophilized powder requiring reconstitution.

• Tablets / capsules: Store at room temperature in a cool, dry place away from light
• Liquid solutions: Refrigerate if specified by the supplier; check formulation-specific guidance
• MK-677 is not a peptide and does not require reconstitution with bacteriostatic water
• No injection preparation is required

Frequently Asked Questions

Is MK-677 a peptide? No. MK-677 (Ibutamoren) is a synthetic small molecule — specifically a spiropiperidine derivative — not a peptide. It does not have an amino acid sequence and is not produced by peptide synthesis methods. It is included on WikiPeptide because it acts on the same ghrelin receptor (GHS-R1a) as the GHRP peptide class and is commonly researched alongside peptide GH secretagogues, but it is pharmacologically distinct from compounds such as Ipamorelin, GHRP-2, and GHRP-6.

How does MK-677 compare to peptide GHRPs like Ipamorelin or GHRP-2? The key practical differences are route of administration and half-life. MK-677 is taken orally (no injection required) and has a ~24-hour half-life enabling once-daily dosing; peptide GHRPs are injected and have half-lives of 15–120 minutes requiring multiple daily injections. MK-677 produces sustained IGF-1 elevation; peptide GHRPs produce discrete pulsatile GH release. Both act via GHS-R1a agonism. MK-677 produces more pronounced water retention and appetite stimulation than Ipamorelin, which is more selective for GH without cortisol or prolactin elevation.

Can MK-677 be combined with GHRH analogues like CJC-1295? Yes. Anecdotal research accounts describe combining MK-677 with GHRH analogues for synergistic GH secretion. The mechanistic rationale is identical to the GHRP + GHRH analogue combination: GHS-R1a agonism (MK-677) and GHRH receptor agonism (CJC-1295 / Sermorelin) activate complementary pathways and produce synergistic GH release.

Does MK-677 suppress natural GH production? Prolonged GHS-R1a stimulation is associated with some attenuation of GH response over time (receptor desensitisation). However, the physiological pulsatile pattern of GH secretion is generally preserved with MK-677, unlike exogenous GH administration which produces complete pituitary suppression. Recovery of baseline GH/IGF-1 levels after MK-677 discontinuation is expected but the timeline is not well characterised in long-term human studies.

Related Pages

Goals: Muscle Growth · Sleep · Longevity

Class: GHRPs — Growth Hormone Releasing Peptides

References & Further Reading

• Chapman IM, et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism, 81(12), 4249–4257. PubMed →
• Svensson J, et al. (1998). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism, 83(2), 362–369. PubMed →
• Nass R, et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601–611. PubMed →
• Copinschi G, et al. (1997). Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 66(4), 278–286. PubMed →